X4 Pharmaceuticals (XFOR) Total Non-Current Liabilities (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Total Non-Current Liabilities for 10 consecutive years, with $97.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities fell 3.55% year-over-year to $97.1 million; the trailing twelve-month figure through Jun 2026 stood at $97.1 million (down 3.55% YoY), and the FY2025 full-year result was $103.2 million, down 6.65% from the prior year.
• Total Non-Current Liabilities retreated to $97.1 million in Q2 2026 per XFOR's latest filing, from $100.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $110.5 million in Q4 2024 and bottomed at $49.3 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $83.4 million across 5 years, with a median of $90.4 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities dropped 8.11% in 2022, then soared 82.22% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $58.4 million in 2022, then surged by 37.82% to $80.5 million in 2023, then jumped by 37.36% to $110.5 million in 2024, then fell by 6.65% to $103.2 million in 2025, then dropped by 5.92% to $97.1 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $97.1 million, $100.9 million, and $103.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.